SuviCa advances SVC112 toward first-in-human clinical trials
SuviCa, a Â鶹Ãâ·Ñ°æÏÂÔØspinout developing novel cancer therapeutics, reached an important regulatory milestone for SVC112, its first-in-class protein synthesis inhibitor for advanced and metastatic solid tumors. Following a Type B pre-IND interaction, the FDA provided positive feedback supporting the program's path toward an IND submission and first-in-human clinical study.Ìý
SVC112 was developed through a research collaboration between Â鶹Ãâ·Ñ°æÏÂÔØBoulder Professor Tin Tin Su (Molecular, Cellular & Developmental Biology) and Â鶹Ãâ·Ñ°æÏÂÔØAnschutz Professor Antonio Jimeno (Medical Oncology), with additional support from the . The milestone highlights the potential for collaborative research across Â鶹Ãâ·Ñ°æÏÂÔØcampuses to translate discoveries from the lab toward commercialization and patient impact.
Tin Tin Su (Professor and Chair, Molecular, Cellular & Developmental Biology, Â鶹Ãâ·Ñ°æÏÂÔØBoulder)